Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Protalix Resubmits To FDA The BLA For Pegunigalsidase Alfa For Treatment Of Fabry Disease

Por: RTTNews Health November 14, 2022

thumbnail

Biopharmaceutical company Protalix BioTherapeutics, Inc. () announced Monday the resubmission on Wednesday of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease.Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked a-galactosidase-A investigational product candidate.The BLA... + full article



Similar News

Valtteri Bottas Is Thriving In Leadership Role With Alfa Romeo

Forbes USA Business October 20, 2022

thumbnailValtteri Bottas of Finland and Alfa Romeo F1 looks on from the drivers parade prior to the F1 Grand ... [+] Prix of Japan at Suzuka International Racing Course. (Photo by Mark Thompson/Getty Images )Getty Images When Valtteri Bottas announced he was joining Alfa Romeo F1 Team... + más

Challenging Formula One Driver Valtteri Bottas In The SBT GRVL Bike Race | Forbes

Zhou to stay with Alfa Romeo in 2023 | ESPN


ALS drug wins FDA approval despite questionable data

ABC News USA Health September 30, 2022

thumbnailWASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | WPLG Local 10


Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval

New York Post USA Life September 30, 2022

thumbnailA much-debated drug for Lou Gehrig’s disease won US approval on Thursday from the Food and Drug Administration. The nod represents a long-desired victory for patients, though it is likely to renew questions about the scientific rigor behind government reviews of... + más

ALS drug wins FDA approval despite questionable data | ABC News

ALS drug gets FDA approval despite uncertainty about effectiveness | ABC7


FDA approves ALS drug partly funded by Ice Bucket Challenge

10 WBNS USA Nation September 30, 2022

thumbnailWASHINGTON — A for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines. The Food and Drug Administration approved the drug from... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News


ALS drug wins FDA approval despite questionable data

WPLG Local 10 USA Politics September 30, 2022

thumbnailWASHINGTON – A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration approved... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News


ALS drug wins FDA approval despite questionable data

Associated Press USA Science September 30, 2022

thumbnailWASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News


Sarepta Submits BLA For SRP-9001 To Treat Ambulant Patients With Duchenne Muscular Dystrophy

RTTNews USA Health September 29, 2022

thumbnailGenetic medicine maker Sarepta Therapeutics, Inc. () announced Thursday that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec) to treat ambulant patients... + más

Diageo Debuts Its 2022 Special Releases Collection | Forbes

Parents of son diagnosed with Duchenne muscular dystrophy are hopeful cure will be found soon | ABC7



About iurex | Privacy Policy | Disclaimer |